Drug acetylation in liver disease

Area of Science:

• Pharmacology
• Drug Metabolism
• Biochemistry

Background:

• N-acetylation is a critical phase II drug metabolism pathway in humans.
• This process is primarily mediated by polymorphic enzymes: N-acetyltransferase 1 (NAT1) and N-acetyltransferase 2 (NAT2).
• Genetic variations in NAT2 lead to distinct acetylator phenotypes (slow, intermediate, rapid).

Purpose of the Study:

• To investigate the impact of liver disease on N-acetylation drug metabolism.
• To evaluate the reliability of NAT2 phenotypic assignments in patients with hepatic dysfunction.
• To assess if standard precautions for slow acetylators are universally applicable in liver cirrhosis.

Main Methods:

• Review of existing literature on drug acetylation and liver disease.
• Analysis of how chronic and acute liver injury affects N-acetyltransferase activity.
• Examination of phenotype-specific effects on NAT2 substrate acetylation.

Main Results:

• Chronic liver disease may modestly decrease drug acetylation, while acute injury has no significant effect.
• Impaired acetylation capacity for NAT2 substrates appears phenotype-specific, notably affecting rapid acetylators more than slow ones.
• Hepatic dysfunction can disrupt the typical bimodal distribution of NAT2 activity, challenging phenotypic assignments.

Conclusions:

• The reliability of NAT2 phenotypic status may be compromised in individuals with significant liver disease.
• Further research is needed to determine if therapeutic guidelines for slow acetylators are appropriate for all patients with liver cirrhosis.
• Understanding these metabolic alterations is crucial for optimizing drug therapy in liver disease patients.